Since the start of our very first EU-funded project with the acronym KINOMED, we have engaged in several other projects by now. The KINOMED project (2010-2013, funded by the Eurostars program) was focused on cloning, expression, purification, and fragment screening of two kinases, PIM1 and CK2, and co-crystallization of the proteins with the best fragments found during the screening. The project was relatively small and involved two other companies (IOTA Pharmaceuticals (UK) and Kinase Detect (Denmark).
The following project, TAKTIC (TrAnslational Kinase Tumor Inhibitor discovery Consortium), involved a larger group of participants, which included ProQinase (Germany), Prestwick Chemical (France), Israel Structural Proteomics Centre at the Weizmann Institute of Science, two academic groups from the University of Turin - the Depts. Of Science and Drug Technology, Medicine, Experimental Oncology, and finally, the TechMedILL platform at the University of Strasbourg. The project was focused on the NF-κB signaling pathway and the design of novel inhibitors of NIK, a MAP3K- kinase responsible for the phosphorylation of IKKα homodimers within the so-called non-canonical NF-κB pathway (see, for example, the NF-κB inhibitors site). This project was finalized in 2015.
The EU also funded our most recent project on the digital transformation of our marketing and sales processes through the Swedish Region Skåne and Tillväxtverket
We also contributed to other EU-funded projects:
BIOCASCADES, Virus-X, PhD4GlycoDrug, SAFER.
You may also view our blog post on our EU projects.